Compare Freshworks Inc (FRSH) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Freshworks Inc vs Johnson & Johnson — how do they compare? Freshworks Inc trades at $10.83 (market cap $2.93B), while Johnson & Johnson trades at $249.52 (market cap $594.63B). The key difference: Johnson & Johnson is far larger — about 202.9× Freshworks Inc's market cap, and Johnson & Johnson pays a 2.17% dividend while Freshworks Inc pays none. Which is the better fit depends on your goals.
| FRSH | JNJ | |
|---|---|---|
Market Cap | $2.93B | $594.63B |
Sector | Technology | Health |
52-Week High | $14.77 | $267.24 |
52-Week Low | $6.88 | $162.98 |
Enterprise Value | $2.19B | $627.57B |
Volume | — | 6,156,228 |
Dividend Yield | — | 2.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Freshworks (FRSH) trades at $10.47, down 3.32% on the day, with a bullish technical signal from moving averages. The company shows a strong fundamental turnaround, achieving profitability in 2025 with a net income margin of 20.69% and robust revenue growth from $498M in 2022 to $839M in 2025. Recent news highlights a strategic pivot to its employee experience (EX) business and new AI product launches, with the Q2 2026 earnings report scheduled for August 4, 2026.
The outlook is positive, supported by a profitable growth trajectory, a 50% analyst buy rating, and a significant valuation discount to software peers. Key risks include execution of the EX pivot, competitive pressures in SaaS, and the need to sustain high gross margins. The stock offers opportunity as a value play with accelerating fundamentals, but faces typical growth stock volatility.
Johnson & Johnson (JNJ) trades at $249.42, down 1.75% over 24 hours, with a bullish technical signal from moving averages but bearish oscillators. The company reported Q2 2026 EPS of $2.90, beating estimates, and raised full-year guidance. Revenue grew 6.6% annually, supported by strong pharmaceutical sales. Analyst consensus is bullish with a $281 price target, and the stock offers a stable dividend with recent payouts of $1.34 per share.
Outlook remains positive due to robust fundamentals, innovation in medtech and pharmaceuticals, and dividend king status. Risks include patent expirations, regulatory pressures, and macroeconomic volatility. The current valuation at P/E 28.66 may limit near-term upside, but long-term growth prospects appear solid.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Freshworks Inc
Freshworks Inc provides software as a service platform that enables small and medium-sized businesses to support customers through e-mail, phone, website, and social networks. It offers solutions that serve the needs of users in the CX and ITSM categories, and have also expanded its offering with Sales and Marketing automation products. These product offerings enable organizations to acquire, engage, and better serve their customers and employees.
Read more on FRSH →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
